Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Polo-like kinase 4 (PLK4) is crucial for centriole duplication, a process often dysregulated in cancer.
• Identifying novel therapeutic targets in human breast cancers is essential for advancing oncology treatments.

Purpose of the Study:

• To identify and validate PLK4 as a therapeutic target in human cancers.
• To develop and evaluate a potent and selective PLK4 inhibitor, CFI-400945, for cancer therapy.

Main Methods:

• Systematic RNAi screening and gene expression analysis in human breast cancer cell lines.
• Drug discovery program to identify a selective PLK4 inhibitor (CFI-400945).
• In vitro studies assessing CFI-400945 effects on cancer cells and in vivo studies using human cancer xenografts in mice.

Main Results:

• CFI-400945 demonstrated potent and selective inhibition of PLK4 kinase activity.
• Treatment with CFI-400945 induced mitotic defects, dysregulated centriole duplication, and cell death in cancer cells.
• Oral administration of CFI-400945 significantly inhibited tumor growth in xenograft models with good tolerability.
• Enhanced antitumor activity was observed in PTEN-deficient tumors compared to PTEN wild-type tumors.

Conclusions:

• PLK4 is a validated therapeutic target for cancer treatment.
• CFI-400945 is a promising PLK4 inhibitor with significant preclinical antitumor activity.
• CFI-400945 warrants clinical evaluation, particularly in solid tumors with PTEN deficiency.